Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Qualitative and quantitative aspects of intercalator-induced DNA strand breaks
1979216 citationsWarren E. Ross, Daniel Glaubiger et al.Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesisprofile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
Countries citing papers authored by Daniel Glaubiger
Since
Specialization
Citations
This map shows the geographic impact of Daniel Glaubiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Glaubiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Glaubiger more than expected).
Fields of papers citing papers by Daniel Glaubiger
This network shows the impact of papers produced by Daniel Glaubiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Glaubiger. The network helps show where Daniel Glaubiger may publish in the future.
Co-authorship network of co-authors of Daniel Glaubiger
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Glaubiger.
A scholar is included among the top collaborators of Daniel Glaubiger based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Daniel Glaubiger. Daniel Glaubiger is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Ungerleider, Richard S., C B Pratt, John S. Holcenberg, et al.. (1985). Phase I trial of mitoxantrone in children.. PubMed. 69(4). 403–7.15 indexed citations
5.
Ramu, A, Daniel Glaubiger, & Z Fuks. (1984). Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.. PubMed. 44(10). 4392–5.166 indexed citations
6.
Ramu, A, Daniel Glaubiger, & Hadassa Weintraub. (1984). Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.. PubMed. 68(4). 637–41.53 indexed citations
Srinivasan, Usha, Gregory H. Reaman, David G. Poplack, Daniel Glaubiger, & C. Elizabeth Shaaban. (1982). Phase II study of 5-azacytidine in sarcomas of bone. American Journal of Clinical Oncology. 5(4). 411–416.9 indexed citations
Riccardi, Riccardo, Bruce A. Chabner, Daniel Glaubiger, James H. Wood, & David G. Poplack. (1982). Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.. PubMed. 42(5). 1736–9.6 indexed citations
Ross, Warren E., Daniel Glaubiger, & Kurt W. Kohn. (1979). Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 562(1). 41–50.216 indexed citations breakdown →
17.
Hoff, Von, et al.. (1978). Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.. PubMed. 62(10). 1421–6.34 indexed citations
Kohn, Kurt W., Michael J. Waring, Daniel Glaubiger, & Charles A. Friedman. (1975). Intercalative binding of ellipticine to DNA.. PubMed. 35(1). 71–6.127 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.